Literature DB >> 11724847

Detection of sporadic cases of hepatitis E virus (HEV) infection in China using immunoassays based on recombinant open reading frame 2 and 3 polypeptides from HEV genotype 4.

Y Wang1, H Zhang, Z Li, W Gu, H Lan, W Hao, R Ling, H Li, T J Harrison.   

Abstract

We reported previously on the complete sequence of hepatitis E virus (HEV) genotype 4, isolated from patients with sporadic cases of acute HEV infection in China. At least eight HEV genotypes have now been described worldwide, and further isolates await classification. Current immunoassays for the detection of anti-HEV antibodies are based on polypeptides from genotypes 1 and 2 only and may be inadequate for the reliable detection of other genotypes. Because genotypes 1 and 4 predominate in China, we wished to investigate the antigenic reactivities of HEV genotype 4 proteins. Four overlapping regions of open reading frame 2 (ORF2) (FB5, amino acids [aa] 1 to 130; E4, aa 67 to 308; F2-2, aa 288 to 461; E5, aa 414 to 672) and the entire ORF3 product were expressed in Escherichia coli as fusion proteins. Enzyme immunoassays based on each of the five purified polypeptides were evaluated with sera from patients with sporadic cases of acute HEV infection. Individual immunoassays derived from HEV genotype 4 detected more cases of acute hepatitis E than a commercial assay. Some serum samples, which were positive for anti-HEV immunoglobulin G only by assays based on HEV genotype 4, were positive for HEV RNA by reverse transcription-PCR. Polypeptide FB5, from the N terminus of ORF2, had the greatest immunoreactivity with sera from patients with acute hepatitis E. These data indicate that the N terminus of ORF2 may provide epitopes which are highly reactive with acute-phase sera and that assays based on genotypes 1 and 2 alone may be inadequate for the detection of HEV infection in China, where sporadic cases of HEV infection are caused predominantly by HEV genotypes 4 and 1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724847      PMCID: PMC88551          DOI: 10.1128/JCM.39.12.4370-4379.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Expression, characterization, and immunoreactivities of a soluble hepatitis E virus putative capsid protein species expressed in insect cells.

Authors:  Y Zhang; P McAtee; P O Yarbough; A W Tam; T Fuerst
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  A novel virus in swine is closely related to the human hepatitis E virus.

Authors:  X J Meng; R H Purcell; P G Halbur; J R Lehman; D M Webb; T S Tsareva; J S Haynes; B J Thacker; S U Emerson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

3.  The impact of traveling to endemic areas on the spread of hepatitis E virus infection: epidemiological and molecular analyses.

Authors:  J C Wu; I J Sheen; T Y Chiang; W Y Sheng; Y J Wang; C Y Chan; S D Lee
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

4.  Autoantibodies present in chronic hepatitis C and chronic hepatitis B viral infections.

Authors:  D L Smalley; M F Hall; C L Broughton
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

5.  Amino-terminal epitopes are exposed when full-length open reading frame 2 of hepatitis E virus is expressed in Escherichia coli, but carboxy-terminal epitopes are masked.

Authors:  F Li; J Torresi; S A Locarnini; H Zhuang; W Zhu; X Guo; D A Anderson
Journal:  J Med Virol       Date:  1997-07       Impact factor: 2.327

6.  Acute hepatitis E by a new isolate acquired in the United States.

Authors:  P Y Kwo; G G Schlauder; H A Carpenter; P J Murphy; J E Rosenblatt; G J Dawson; E E Mast; K Krawczynski; V Balan
Journal:  Mayo Clin Proc       Date:  1997-12       Impact factor: 7.616

7.  Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group.

Authors:  E E Mast; M J Alter; P V Holland; R H Purcell
Journal:  Hepatology       Date:  1998-03       Impact factor: 17.425

8.  Purification of a soluble hepatitis E open reading frame 2-derived protein with unique antigenic properties.

Authors:  C P McAtee; Y Zhang; P O Yarbough; T Bird; T R Fuerst
Journal:  Protein Expr Purif       Date:  1996-09       Impact factor: 1.650

9.  Existing variations on the gene structure of hepatitis E virus strains from some regions of China.

Authors:  R Huang; N Nakazono; K Ishii; O Kawamata; R Kawaguchi; Y Tsukada
Journal:  J Med Virol       Date:  1995-12       Impact factor: 2.327

10.  Identification of a novel strain of hepatitis E virus responsible for sporadic acute hepatitis in Taiwan.

Authors:  S Y Hsieh; P Y Yang; Y P Ho; C M Chu; Y F Liaw
Journal:  J Med Virol       Date:  1998-08       Impact factor: 2.327

View more
  18 in total

1.  Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections.

Authors:  Florence Legrand-Abravanel; Isabelle Thevenet; Jean-Michel Mansuy; Karine Saune; Françoise Vischi; Jean-Marie Peron; Nassim Kamar; Lionel Rostaing; Jacques Izopet
Journal:  Clin Vaccine Immunol       Date:  2009-03-25

2.  Restricted enzooticity of hepatitis E virus genotypes 1 to 4 in the United States.

Authors:  Chen Dong; Jihong Meng; Xing Dai; Jiu-Hong Liang; Alicia R Feagins; Xiang-Jin Meng; Natalia M Belfiore; Carol Bradford; Joseph L Corn; Carolyn Cray; Gregory E Glass; Melvin L Gordon; Richard A Hesse; Donald L Montgomery; William L Nicholson; Anthony A Pilny; Sheela Ramamoorthy; Douglas D Shaver; Jan Drobeniuc; Michael A Purdy; Howard A Fields; Saleem Kamili; Chong-Gee Teo
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

Review 3.  Hepatitis E: an overview and recent advances in vaccine research.

Authors:  Ling Wang; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

4.  Polyphyletic strains of hepatitis E virus are responsible for sporadic cases of acute hepatitis in Japan.

Authors:  Hitoshi Mizuo; Kazuyuki Suzuki; Yasuhiro Takikawa; Yoshiki Sugai; Hajime Tokita; Yoshihiro Akahane; Keiichi Itoh; Yuhko Gotanda; Masaharu Takahashi; Tsutomu Nishizawa; Hiroaki Okamoto
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

5.  A single amino acid substitution changes antigenicity of ORF2-encoded proteins of hepatitis E virus.

Authors:  Jiu-Hong Liang; Xing Dai; Chen Dong; Ji-Hong Meng
Journal:  Int J Mol Sci       Date:  2010-08-12       Impact factor: 5.923

6.  Deletions of the hypervariable region (HVR) in open reading frame 1 of hepatitis E virus do not abolish virus infectivity: evidence for attenuation of HVR deletion mutants in vivo.

Authors:  R S Pudupakam; Y W Huang; T Opriessnig; P G Halbur; F W Pierson; X J Meng
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

7.  Clinical significance of anti-HEV IgA in diagnosis of acute genotype 4 hepatitis E virus infection negative for anti-HEV IgM.

Authors:  Shujun Zhang; Deying Tian; Zhengang Zhang; Junhui Xiong; Quan Yuan; Shengxiang Ge; Jun Zhang; Ningshao Xia
Journal:  Dig Dis Sci       Date:  2009-01-01       Impact factor: 3.199

8.  Swine hepatitis E virus in rural southern China: genetic characterization and experimental infection in rhesus monkeys (Macaca mulatta).

Authors:  Yanli Ji; Yonghong Zhu; Jingrui Liang; Xianfei Wei; Xi Yang; Ling Wang; Lingjun Li; Yibin Chang; Ronglan Tang; Hui Zhuang
Journal:  J Gastroenterol       Date:  2008-07-23       Impact factor: 7.527

9.  Duration of viraemia in Chinese acute sporadic hepatitis E.

Authors:  Y-H Lu; H-Z Qian; A-Q Hu; H Ren; X Qin; Q-W Jiang; Y-J Zheng
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-11-16       Impact factor: 3.267

10.  Use of immuno-dominant epitope derived from genotype 4 as a diagnostic reagent for detecting the antibodies against Hepatitis E Virus.

Authors:  Bing-shui Xiu; Xiao-yan Feng; Jing He; Kun Chen; Jing Liu; Zhen-hua Dai; Xi-qin Yang; Guo-hua Wang; You-chun Wang; He-qiu Zhang; Xiao-guo Song; Cui-xia Zhu
Journal:  Virol J       Date:  2013-04-25       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.